Skip to main content

Psyence Biomedical Ltd.

corporate_fare Company Profile

Psyence Biomedical Ltd.

PBM·NASDAQ·Life Sciences·CIK 0001985062

PSYENCE BIOMEDICAL LTD. is a company that engages in clinical research, specifically managing a Phase IIb Study through its wholly-owned subsidiary, Psyence Australia. On May 21, 2025, Psyence Australia entered into a Master Services Agreement (MSA) with Southern Star Research, which will act as the Contract Research Organization (CRO) for the Company's registrational Phase IIb Study. Southern Star Research will provide a range of CRO services, including Trial Management & Oversight, which covers clinical monitoring, site initiation, site management, and close-out activities. They will also handle Project Management, involving the development and maintenance of a detailed project plan, coordination of teams, and status reporting. Data Management & Biostatistics services include designing, building, and maintaining the electronic data capture (EDC) system, data cleaning, database lock, and generating statistical reports. Regulatory & Ethics Support involves preparing submissions to the Therapeutic Goods Administration (TGA) in Australia and local ethics committees, as well as managing regulatory correspondence. Pharmacovigilance & Safety Oversight includes collecting, processing, and reporting adverse events. Patient Recruitment & Retention assistance will focus on site selection, patient screening, and retention programs to enroll the target 87 participants in the double-blind, placebo-controlled study. Finally, Transitional Handover will coordinate with the Company's prior CRO, iNGEN, for a seamless transition. The Company will pay Southern Star Research aggregate fees, structured as an upfront deposit (a percentage of total project costs) and monthly invoices for services delivered, plus reimbursement for out-of-pocket costs.

Psyence Biomedical Ltd. (NASDAQ:PBM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for PBM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for PBM spans 6-K, SCHEDULE 13D/A, 20-F, SCHEDULE 13D.

Recent high-impact activity:

  • Psyence BioMed Posts $1.94M H1 Loss, $21.1M Cash; PsyLabs Stake Hits 43.4%
  • Psyence Completes US$2.6M PsyLabs Backstop as Ibogaine Milestones Met
  • PsyLabs Closes Swap, Holds 49.75% of Psyence Biomedical at US$6.00/Share
  • Psyence BioMed Adds DEA-Registered Benuvia for U.S. Ibogaine Manufacturing
  • Psyence BioMed's Texas Subsidiary Secures Exclusive U.S. Ibogaine License from Related-Party PsyLabs

Financial Snapshot

Fiscal year ended March 31, 2026
Net Income
-$6.94M
Diluted EPS
-$12.56
Op. Cash Flow
-$8.14M
Free Cash Flow
-$8.14M
Cash & Equivalents
$7.44M
Debt / Equity
0.00×
Shares Outstanding
2.44K sh
Source: 20-F · filed 2026-06-22 · accession 0001213900-26-070607

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 19,062 shares in PBM as of the October 30, 2026 settlement, a 6.1% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 27.3% of PBM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)19,062 shares as of October 30, 2026
Change vs prior period▼ 6.1%
Days to cover1.00 at avg daily volume of 57,987
Daily short volume (FINRA facilities)27.3% of 14,313 shares on November 20, 2026
5-day average short volume30.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for PBM, detected from its recent SEC filings · based on capital-structure filings through 2026-06-22.

1 shelf registration

Significant Net Loss Reported · Massive Dilution from Equity Line of Credit

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

PBM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with P →
$3.01 +1.19% today
52-week range · as of 2026-11-19 $1.92 – $18.31
Market cap
$11.33M
Volume
32.7K (0.6× avg)
3-mo avg 50.8K
Live data · 2026-11-21 05:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PBM - Latest Insights

PBM
Nov 19, 2026, 8:00 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.60
Real-time Price: $3.01 info
Change: +$0.4047 (+16%) info
Market Cap: $11.329M info
PBM
Oct 21, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.09
Real-time Price: $3.01 info
Change: -$1.08 (-27%) info
Market Cap: $11.329M info
PBM
Oct 15, 2026, 9:03 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $4.00
Real-time Price: $3.01 info
Change: -$0.9946 (-25%) info
Market Cap: $11.329M info
PBM
Oct 05, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.35
Real-time Price: $3.01 info
Change: -$2.34 (-44%) info
Market Cap: $11.329M info
PBM
Sep 28, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.86
Real-time Price: $3.01 info
Change: -$2.85 (-49%) info
Market Cap: $11.329M info
PBM
Sep 23, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $6.42
Real-time Price: $3.01 info
Change: -$3.41 (-53%) info
Market Cap: $11.329M info
PBM
Jun 22, 2026, 4:01 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $3.10
Real-time Price: $3.01 info
Change: -$0.0946 (-3%) info
Market Cap: $11.329M info
PBM
Jun 03, 2026, 9:28 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $4.00
Real-time Price: $3.01 info
Change: -$0.9946 (-25%) info
Market Cap: $11.329M info
PBM
May 15, 2026, 9:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.47
Real-time Price: $3.01 info
Change: -$2.46 (-45%) info
Market Cap: $11.329M info
PBM
Apr 23, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $9.02
Real-time Price: $3.01 info
Change: -$6.01 (-67%) info
Market Cap: $11.329M info
PBM
Apr 20, 2026, 8:25 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.27
Real-time Price: $3.01 info
Change: -$11.26 (-79%) info
Market Cap: $11.329M info
PBM
Apr 17, 2026, 4:59 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $8.68
Real-time Price: $3.01 info
Change: -$5.67 (-65%) info
Market Cap: $11.329M info
PBM
Apr 17, 2026, 9:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.82
Real-time Price: $3.01 info
Change: -$6.81 (-69%) info
Market Cap: $11.329M info
PBM
Apr 08, 2026, 9:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.67
Real-time Price: $3.01 info
Change: +$0.3354 (+13%) info
Market Cap: $11.329M info
PBM
Mar 03, 2026, 9:15 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $2.28
Real-time Price: $3.01 info
Change: +$0.7254 (+32%) info
Market Cap: $11.329M info
PBM
Mar 02, 2026, 7:07 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.45
Real-time Price: $3.01 info
Change: +$0.5554 (+23%) info
Market Cap: $11.329M info
PBM
Feb 20, 2026, 5:25 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.00
Real-time Price: $3.01 info
Change: +$0.0054 (+0.18%) info
Market Cap: $11.329M info
PBM
Feb 19, 2026, 7:19 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.60
Real-time Price: $3.01 info
Change: +$0.4054 (+16%) info
Market Cap: $11.329M info
PBM
Feb 13, 2026, 4:01 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.09
Real-time Price: $3.01 info
Change: -$0.0846 (-3%) info
Market Cap: $11.329M info
PBM
Feb 12, 2026, 8:40 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.92
Real-time Price: $3.01 info
Change: +$0.0854 (+3%) info
Market Cap: $11.329M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets